Objective To explore the effect of interferon α2b combined with acyclovir on immune function in children with viral pneumonia.
Methods A total of 150 children with viral pneumonia were randomly divided into blank control group, control group and observation group, with 50 cases in each group. The blank control group did not receive any antiviral drugs, the control group was given acyclovir in addition to conventional treatment, and the observation group was given recombinant human interferon α2b injection on the basis of the control group. The improvement of clinical symptoms was compared. The levels of T lymphocyte subsets, inflammatory factors amyloid A (SAA) and high-sensitivity C-reactive protein (hs-CRP)were measured, and the clinical efficacy was analyzed.
Results After treatment, the improvement time of clinical symptoms in the observation group was significantly shorter than that in the blank control group and control group (P < 0.05); after treatment, the serum levels of CD4+, CD4+/CD8+, SAA and hs-CRP were significantly lower, while the levels of CD3+ and CD8+ were significantly higher than before treatment (P < 0.05); the serum levels of CD4+, CD4+/CD8+, SAA and hs-CRP in the observation group were significantly lower, while the levels of CD3+ and CD8+ were significantly higher than those in the blank control group and control group (P < 0.05). The total effective rate of the observation group was significantly higher than that of the blank control group and control group (P < 0.05).
Conclusion Interferon α2b combined with acyclovir is effective in the treatment of children with viral pneumonia, which can effectively improve the clinical symptoms, enhance the immune capacity of children, inhibit the inflammatory response, and is conductive to the outcome of the disease.
DownLoad: